Nautilus Biotechnology, Inc. is a development stage life sciences company, which creates platform technology for quantifying and unlocking the complexity of the proteome. The company is headquartered in Seattle, Washington and currently employs 134 full-time employees. The company went IPO on 2020-08-07. The firm is engaged in creating platform technology for quantifying and unlocking the complexity of the human proteome. The firm is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The firm's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.
Follow-Up Questions
Who is the CEO of Nautilus Biotechnology Inc?
Mr. Sujal Patel is the President of Nautilus Biotechnology Inc, joining the firm since 2021.
What is the price performance of NAUT stock?
The current price of NAUT is $0.7116, it has decreased 2.37% in the last trading day.
What are the primary business themes or industries for Nautilus Biotechnology Inc?
Nautilus Biotechnology Inc belongs to Life Sciences Tools & Services industry and the sector is Health Care
What is Nautilus Biotechnology Inc market cap?
Nautilus Biotechnology Inc's current market cap is $89.8M
Is Nautilus Biotechnology Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Nautilus Biotechnology Inc, including 3 strong buy, 4 buy, 1 hold, 0 sell, and 3 strong sell
